Trial Profile
Phase II Pharmacogenomic and Clinical Trial for the Administration of Gemcitabine-doxorubicin-paclitaxel (GAT) as Neoadjuvant Treatment of Patients With Stage III Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 05 Jun 2009 New trial record.